Hoth Therapeutics announces positive data from skin toxicities with HT-001

Hoth Therapeutics announced positive data from the treatment of epidermal growth factor receptor inhibitor – EGFRI – associated papulopustular eruptions with its novel therapeutic HT-001. During this first-of-its-kind human patient case, the patient was able to cease treatment after just one week due to the rapid and successful resolution of symptoms, marking a significant advancement in managing a common and debilitating side effect experienced by cancer patients undergoing EGFRI therapy. In the reported case, the patient, a 59-year-old female undergoing treatment for metastatic breast cancer, experienced significant improvement in symptoms just one week after initiating HT-001 therapy. Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days. Over the following three weeks, no new lesions developed, further highlighting the potential of HT-001 as an effective and safe therapy for EGFRI-associated PPEs. A Phase 2a clinical trial is currently underway to further evaluate the efficacy and safety of HT-001 in the management of EGFRI-associated skin toxicities.